<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738892</url>
  </required_header>
  <id_info>
    <org_study_id>14-2113</org_study_id>
    <nct_id>NCT02738892</nct_id>
  </id_info>
  <brief_title>Zambian Prematurity Prevention Study</brief_title>
  <official_title>Z 1401 - Preventing Preterm Birth in Zambia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Global Alliance to Prevent Prematurity and Stillbirth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective non-intervention cohort study will enroll women in the first or early second
      trimester of pregnancy and follow them through delivery and 42 days postpartum.

      Infants will also be followed until 42 days after delivery. Detailed medical and obstetrical
      information will be collected, as well as biological samples, in order to better elucidate
      the biological mechanisms leading to preterm delivery among Zambian women, in an effort to
      identify new strategies for prevention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After consenting to study participation, women will be asked their detailed medical and
      obstetrical history. Participants will be provided standard of care. Blood, urine, and
      vaginal specimens will also be collected for the biorepository from those who consent to
      participate. Participants will also be screened for depression using the Edinburgh Postnatal
      Depression Scale (EPDS).

      Throughout the study, participants will receive education about nutrition, pregnancy health,
      and the signs and symptoms of complications of pregnancy, including preterm labor and preterm
      premature rupture of membranes. Study visits for will be scheduled at 24, 28, 32, and 36
      weeks gestation, and also at the time of discharge from the hospital after delivery if
      possible.

      During antenatal each study visit (i.e., at 24, 32, and 36 weeks gestation), participants
      will receive the routinely recommended screening and treatment. This will consist of weight,
      blood pressure, and symptom screening, as well as measurements of fetal growth (fundal
      height) and fetal well being (fetal heart rate) at each visit. Screening and treatment of
      common pregnancy complications will also be provided if clinically indicated. An additional
      fetal biometry ultrasound will be performed at 32 weeks. At 24 and 28 weeks, blood, urine,
      and vaginal swabs will be collected. HIV testing will be repeated at 28 weeks.

      At the time of delivery, the study team will obtain detailed information about the clinical
      management of the participant's delivery, as well as the delivery outcome for both the mother
      and her infant(s). Information on interval complications and mortality at the time that the
      mother and/or her infant(s) are discharged from hospital will also be obtained.

      There will be one study visit during the postnatal period, at 42-days post-partum. At this
      visit, routinely recommended screening and treatment will be provided. Participants will be
      screened for depression using the EPDS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of preterm births per 100 person years</measure>
    <time_frame>Measured at the delivery</time_frame>
    <description>Incidence rate of preterm birth (delivery &lt;37 weeks gestation)</description>
  </primary_outcome>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Pregnancy</condition>
  <condition>Stillbirth</condition>
  <condition>Preterm Birth</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, vaginal, placental, and umbilical cord samples will be placed in a
      biorepository for later analysis to identify inflammatory markers, chemokines, cytokines, and
      infections contributing to parturition and preterm delivery.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will be conducted at Kamwala Health Centre and the University Teaching Hospital,
        both in Lusaka, Zambia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pregnant women ≥18 years will be eligible to participate. Additionally, participants will:

          1. Have a completed screening ultrasound with gestational age &lt; 16 weeks

          2. Be HIV-uninfected at enrollment

          3. Have a singleton or twin pregnancy with fetal heart tones confirmed by ultrasound

          4. Reside within Lusaka with no plans to relocate during the study follow-up period

          5. Be willing to provide written, informed consent

          6. Be willing to allow their infants to participate in the study

        Exclusion criteria:

          1. Pregnant women &gt; 24 weeks' gestation or with screening ultrasound ≥ 16 weeks

          2. Infants born to women not enrolled in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Stringer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joan Price, MD, MPH</last_name>
    <phone>260 966 668 312</phone>
    <email>joan_price@med.unc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kamwala Health Centre</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Price, MD</last_name>
      <phone>260 966 668 312</phone>
      <email>joan_price@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Price, MD</last_name>
      <phone>260 966 668 312</phone>
      <email>joan_price@med.unc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <link>
    <url>http://www.unc.edu</url>
    <description>University of North Carolina website</description>
  </link>
  <reference>
    <citation>Lawn JE, Kinney MV, Black RE, Pitt C, Cousens S, Kerber K, Corbett E, Moran AC, Morrissey CS, Oestergaard MZ. Newborn survival: a multi-country analysis of a decade of change. Health Policy Plan. 2012 Jul;27 Suppl 3:iii6-28. doi: 10.1093/heapol/czs053. Erratum in: Health Policy Plan. 2013 Oct;28(7):786-8.</citation>
    <PMID>22692417</PMID>
  </reference>
  <reference>
    <citation>Nour NM. Premature delivery and the millennium development goal. Rev Obstet Gynecol. 2012;5(2):100-5.</citation>
    <PMID>22866189</PMID>
  </reference>
  <reference>
    <citation>Wang ML, Dorer DJ, Fleming MP, Catlin EA. Clinical outcomes of near-term infants. Pediatrics. 2004 Aug;114(2):372-6.</citation>
    <PMID>15286219</PMID>
  </reference>
  <reference>
    <citation>Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L, Lawn JE. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012 Jun 9;379(9832):2162-72. doi: 10.1016/S0140-6736(12)60820-4.</citation>
    <PMID>22682464</PMID>
  </reference>
  <reference>
    <citation>March of Dimes P, Save the Children, WHO. Born Too Soon: The Global Action Report on Preterm Birth. In. Edited by Eds CP Howson MK, JE Lawn. Geneva: World Health Organization; 2012.</citation>
  </reference>
  <reference>
    <citation>Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008 Jan 5;371(9606):75-84. doi: 10.1016/S0140-6736(08)60074-4. Review.</citation>
    <PMID>18177778</PMID>
  </reference>
  <reference>
    <citation>Oliver RS, Lamont RF. Infection and antibiotics in the aetiology, prediction and prevention of preterm birth. J Obstet Gynaecol. 2013 Nov;33(8):768-75. doi: 10.3109/01443615.2013.842963. Review.</citation>
    <PMID>24219711</PMID>
  </reference>
  <reference>
    <citation>Gotsch F, Gotsch F, Romero R, Erez O, Vaisbuch E, Kusanovic JP, Mazaki-Tovi S, Kim SK, Hassan S, Yeo L. The preterm parturition syndrome and its implications for understanding the biology, risk assessment, diagnosis, treatment and prevention of preterm birth. J Matern Fetal Neonatal Med. 2009;22 Suppl 2:5-23. doi: 10.1080/14767050902860690.</citation>
    <PMID>19951079</PMID>
  </reference>
  <reference>
    <citation>Lawn JE, Cousens S, Zupan J; Lancet Neonatal Survival Steering Team. 4 million neonatal deaths: when? Where? Why? Lancet. 2005 Mar 5-11;365(9462):891-900.</citation>
    <PMID>15752534</PMID>
  </reference>
  <reference>
    <citation>Iams JD. Clinical practice. Prevention of preterm parturition. N Engl J Med. 2014 Jan 16;370(3):254-61. doi: 10.1056/NEJMcp1103640. Review.</citation>
    <PMID>24428470</PMID>
  </reference>
  <reference>
    <citation>Muglia LJ, Katz M. The enigma of spontaneous preterm birth. N Engl J Med. 2010 Feb 11;362(6):529-35. doi: 10.1056/NEJMra0904308. Review.</citation>
    <PMID>20147718</PMID>
  </reference>
  <reference>
    <citation>Kim CJ, Romero R, Kusanovic JP, Yoo W, Dong Z, Topping V, Gotsch F, Yoon BH, Chi JG, Kim JS. The frequency, clinical significance, and pathological features of chronic chorioamnionitis: a lesion associated with spontaneous preterm birth. Mod Pathol. 2010 Jul;23(7):1000-11. doi: 10.1038/modpathol.2010.73. Epub 2010 Mar 26.</citation>
    <PMID>20348884</PMID>
  </reference>
  <reference>
    <citation>Myatt L, Eschenbach DA, Lye SJ, Mesiano S, Murtha AP, Williams SM, Pennell CE; International Preterm Birth Collaborative Pathways and Systems Biology Working Groups. A standardized template for clinical studies in preterm birth. Reprod Sci. 2012 May;19(5):474-82. doi: 10.1177/1933719111426602. Epub 2012 Feb 16.</citation>
    <PMID>22344727</PMID>
  </reference>
  <reference>
    <citation>Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, Chaiworapongsa T, Mazor M. The preterm parturition syndrome. BJOG. 2006 Dec;113 Suppl 3:17-42. Review. Erratum in: BJOG. 2008 Apr;115(5):674-5.</citation>
    <PMID>17206962</PMID>
  </reference>
  <reference>
    <citation>Romero R, Espinoza J, Gotsch F, Kusanovic JP, Friel LA, Erez O, Mazaki-Tovi S, Than NG, Hassan S, Tromp G. The use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome. BJOG. 2006 Dec;113 Suppl 3:118-35. Review. Erratum in: BJOG. 2008 Apr;115(5):674-5.</citation>
    <PMID>17206980</PMID>
  </reference>
  <reference>
    <citation>Liong S, Di Quinzio MK, Fleming G, Permezel M, Rice GE, Georgiou HM. Prediction of spontaneous preterm labour in at-risk pregnant women. Reproduction. 2013 Aug 21;146(4):335-45. doi: 10.1530/REP-13-0175. Print 2013 Oct.</citation>
    <PMID>23858477</PMID>
  </reference>
  <reference>
    <citation>Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987 Jun;150:782-6.</citation>
    <PMID>3651732</PMID>
  </reference>
  <reference>
    <citation>Wisner KL, Parry BL, Piontek CM. Clinical practice. Postpartum depression. N Engl J Med. 2002 Jul 18;347(3):194-9. Review.</citation>
    <PMID>12124409</PMID>
  </reference>
  <reference>
    <citation>Aleman A, Cafferata ML, Gibbons L, Althabe F, Ortiz J, Sandoval X, Padilla-Raygoza N, Belizán JM. Use of antenatal corticosteroids for preterm birth in Latin America: providers knowledge, attitudes and practices. Reprod Health. 2013 Jan 29;10:4. doi: 10.1186/1742-4755-10-4.</citation>
    <PMID>23360713</PMID>
  </reference>
  <reference>
    <citation>Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev. 2000;(2):CD000065. Review. Update in: Cochrane Database Syst Rev. 2006;(3):CD000065.</citation>
    <PMID>10796110</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Stillbirth</keyword>
  <keyword>Preterm birth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Stillbirth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

